Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2025-12-25 @ 8:22 PM
Study NCT ID:
NCT01522469
Status:
COMPLETED
Last Update Posted:
2024-01-30
First Post:
2012-01-30
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Sponsor:
Arog Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-07
Start Date Type:
None
Primary Completion Date:
2014-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-11
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-30
First Submit QC Date:
None
Study First Post Date:
2012-01-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-12-05
Results First Submit QC Date:
None
Results First Post Date:
2024-01-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-06-28
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-01-03
Last Update Post Date:
2024-01-30
Last Update Post Date Type:
ACTUAL